733 related articles for article (PubMed ID: 27927963)
1. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
Svarcbahs R; Julku UH; Myöhänen TT
J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
[TBL] [Abstract][Full Text] [Related]
2. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.
Savolainen MH; Richie CT; Harvey BK; Männistö PT; Maguire-Zeiss KA; Myöhänen TT
Neurobiol Dis; 2014 Aug; 68():1-15. PubMed ID: 24746855
[TBL] [Abstract][Full Text] [Related]
3. Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture.
Myöhänen TT; Norrbacka S; Savolainen MH
Neurosci Lett; 2017 Jan; 636():83-89. PubMed ID: 27818354
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers.
Dokleja L; Hannula MJ; Myöhänen TT
Neurosci Lett; 2014 Nov; 583():37-42. PubMed ID: 25240592
[TBL] [Abstract][Full Text] [Related]
5. Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interaction.
Savolainen MH; Yan X; Myöhänen TT; Huttunen HJ
J Biol Chem; 2015 Feb; 290(8):5117-5126. PubMed ID: 25555914
[TBL] [Abstract][Full Text] [Related]
6. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
Myöhänen TT; Hannula MJ; Van Elzen R; Gerard M; Van Der Veken P; García-Horsman JA; Baekelandt V; Männistö PT; Lambeir AM
Br J Pharmacol; 2012 Jun; 166(3):1097-113. PubMed ID: 22233220
[TBL] [Abstract][Full Text] [Related]
7. Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo.
Svarcbahs R; Julku UH; Norrbacka S; Myöhänen TT
Sci Rep; 2018 Jan; 8(1):1552. PubMed ID: 29367610
[TBL] [Abstract][Full Text] [Related]
8. Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells.
Rostami J; Jäntti M; Cui H; Rinne MK; Kukkonen JP; Falk A; Erlandsson A; Myöhänen T
Biomed Pharmacother; 2020 Nov; 131():110788. PubMed ID: 33152946
[TBL] [Abstract][Full Text] [Related]
9. Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy.
Cui H; Norrbacka S; Myöhänen TT
Biochem Pharmacol; 2022 Mar; 197():114899. PubMed ID: 34968496
[TBL] [Abstract][Full Text] [Related]
10. Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model.
Eteläinen TS; Kilpeläinen TP; Ignatius A; Auno S; De Lorenzo F; Uhari-Väänänen JK; Julku UH; Myöhänen TT
Neuropharmacology; 2022 Nov; 218():109213. PubMed ID: 35964686
[TBL] [Abstract][Full Text] [Related]
11. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
[TBL] [Abstract][Full Text] [Related]
12. Prolyl oligopeptidase inhibition reduces alpha-synuclein aggregation in a cellular model of multiple system atrophy.
Cui H; Kilpeläinen T; Zouzoula L; Auno S; Trontti K; Kurvonen S; Norrbacka S; Hovatta I; Jensen PH; Myöhänen TT
J Cell Mol Med; 2021 Oct; 25(20):9634-9646. PubMed ID: 34486218
[TBL] [Abstract][Full Text] [Related]
13. Prolyl Oligopeptidase Regulates Dopamine Transporter Phosphorylation in the Nigrostriatal Pathway of Mouse.
Julku UH; Panhelainen AE; Tiilikainen SE; Svarcbahs R; Tammimäki AE; Piepponen TP; Savolainen MH; Myöhänen TT
Mol Neurobiol; 2018 Jan; 55(1):470-482. PubMed ID: 27966077
[TBL] [Abstract][Full Text] [Related]
14. The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy.
Kilpeläinen TP; Hellinen L; Vrijdag J; Yan X; Svarcbahs R; Vellonen KS; Lambeir AM; Huttunen H; Urtti A; Wallen EAA; Myöhänen TT
Biomed Pharmacother; 2020 Aug; 128():110253. PubMed ID: 32447211
[TBL] [Abstract][Full Text] [Related]
15. New tricks of prolyl oligopeptidase inhibitors - A common drug therapy for several neurodegenerative diseases.
Svarcbahs R; Julku U; Kilpeläinen T; Kyyrö M; Jäntti M; Myöhänen TT
Biochem Pharmacol; 2019 Mar; 161():113-120. PubMed ID: 30660495
[TBL] [Abstract][Full Text] [Related]
16. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
17. Extracellular prolyl oligopeptidase derived from activated microglia is a potential neuroprotection target.
Natunen TA; Gynther M; Rostalski H; Jaako K; Jalkanen AJ
Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):40-49. PubMed ID: 29998529
[TBL] [Abstract][Full Text] [Related]
18. Transgenic Mice Expressing Human α-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson's Disease.
Butkovich LM; Houser MC; Chalermpalanupap T; Porter-Stransky KA; Iannitelli AF; Boles JS; Lloyd GM; Coomes AS; Eidson LN; De Sousa Rodrigues ME; Oliver DL; Kelly SD; Chang J; Bengoa-Vergniory N; Wade-Martins R; Giasson BI; Joers V; Weinshenker D; Tansey MG
J Neurosci; 2020 Sep; 40(39):7559-7576. PubMed ID: 32868457
[TBL] [Abstract][Full Text] [Related]
19. Inhibition-mediated changes in prolyl oligopeptidase dynamics possibly related to α-synuclein aggregation.
Walczewska-Szewc K; Rydzewski J; Lewkowicz A
Phys Chem Chem Phys; 2022 Feb; 24(7):4366-4373. PubMed ID: 35112120
[TBL] [Abstract][Full Text] [Related]
20. KYP-2047 penetrates mouse brain and effectively inhibits mouse prolyl oligopeptidase.
Jalkanen AJ; Leikas JV; Forsberg MM
Basic Clin Pharmacol Toxicol; 2014 Jun; 114(6):460-3. PubMed ID: 24350801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
